$9.48
2.57% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US30052C1071
Symbol
EOLS
Sector
Industry

Evolus, Inc. Stock price

$9.48
-0.76 7.42% 1M
-0.32 3.27% 6M
-1.56 14.13% YTD
-2.20 18.84% 1Y
-3.80 28.61% 3Y
+6.42 209.80% 5Y
-2.02 17.57% 10Y
-2.02 17.57% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.25 2.57%
ISIN
US30052C1071
Symbol
EOLS
Sector
Industry

Key metrics

Basic
Market capitalization
$611.2m
Enterprise Value
$665.1m
Net debt
$53.9m
Cash
$67.9m
Shares outstanding
64.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.2 | 1.7
EV/Sales
2.4 | 1.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
2.4%
Return on Equity
-913.1%
ROCE
-21.0%
ROIC
-30.2%
Debt/Equity
-18.5
Financials (TTM | estimate)
Revenue
$275.5m | $355.3m
EBITDA
$-28.1m | $12.4m
EBIT
$-32.9m | $2.7m
Net Income
$-56.2m | $-8.2m
Free Cash Flow
$-28.9m
Growth (TTM | estimate)
Revenue
25.4% | 33.4%
EBITDA
12.5% | 153.6%
EBIT
12.2% | 110.0%
Net Income
6.3% | 83.8%
Free Cash Flow
-11.4%
Margin (TTM | estimate)
Gross
68.1%
EBITDA
-10.2% | 3.5%
EBIT
-12.0%
Net
-20.4% | -2.3%
Free Cash Flow
-10.5%
More
EPS
$-0.9
FCF per Share
$-0.4
Short interest
16.8%
Employees
332
Rev per Employee
$800.0k
Show more

Is Evolus, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Evolus, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Evolus, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Evolus, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Evolus, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
275 275
25% 25%
100%
- Direct Costs 88 88
30% 30%
32%
188 188
23% 23%
68%
- Selling and Administrative Expenses 210 210
21% 21%
76%
- Research and Development Expense 9.31 9.31
20% 20%
3%
-28 -28
13% 13%
-10%
- Depreciation and Amortization 4.78 4.78
10% 10%
2%
EBIT (Operating Income) EBIT -33 -33
12% 12%
-12%
Net Profit -56 -56
6% 6%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Evolus, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evolus, Inc. Stock News

Neutral
Business Wire
2 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee ...
Neutral
Business Wire
4 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinum toxin type A) in France. Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to ...
Neutral
Business Wire
about one month ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company's common stock to 17 newly hired non-execut...
More Evolus, Inc. News

Company Profile

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

Head office United States
CEO David Moatazedi
Employees 332
Founded 2012
Website www.evolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today